John G Ullman & Associates Inc. Reduces Position in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

John G Ullman & Associates Inc. trimmed its holdings in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 0.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 55,043 shares of the company’s stock after selling 438 shares during the quarter. John G Ullman & Associates Inc.’s holdings in GE HealthCare Technologies were worth $4,303,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Fisher Asset Management LLC increased its position in shares of GE HealthCare Technologies by 6.9% during the fourth quarter. Fisher Asset Management LLC now owns 3,624 shares of the company’s stock worth $283,000 after acquiring an additional 233 shares during the last quarter. Bank OZK purchased a new stake in shares of GE HealthCare Technologies during the fourth quarter worth about $1,700,000. SVB Wealth LLC purchased a new stake in shares of GE HealthCare Technologies during the fourth quarter worth about $417,000. Argyle Capital Management LLC increased its holdings in GE HealthCare Technologies by 32.1% in the fourth quarter. Argyle Capital Management LLC now owns 15,782 shares of the company’s stock valued at $1,234,000 after buying an additional 3,838 shares during the last quarter. Finally, Anchor Capital Advisors LLC increased its holdings in GE HealthCare Technologies by 56.7% in the fourth quarter. Anchor Capital Advisors LLC now owns 441,744 shares of the company’s stock valued at $34,536,000 after buying an additional 159,851 shares during the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on GEHC. Wells Fargo & Company boosted their price objective on GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Citigroup boosted their price objective on GE HealthCare Technologies from $103.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Finally, Jefferies Financial Group raised GE HealthCare Technologies from a “hold” rating to a “buy” rating and boosted their price objective for the company from $95.00 to $103.00 in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $97.67.

GE HealthCare Technologies Price Performance

Shares of NASDAQ:GEHC opened at $87.35 on Friday. The company has a market cap of $39.94 billion, a P/E ratio of 20.17, a price-to-earnings-growth ratio of 3.19 and a beta of 1.15. GE HealthCare Technologies Inc. has a 12-month low of $74.51 and a 12-month high of $94.80. The company’s fifty day moving average is $86.17 and its two-hundred day moving average is $86.12. The company has a quick ratio of 0.83, a current ratio of 1.04 and a debt-to-equity ratio of 0.88.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.19. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. The firm had revenue of $5.32 billion during the quarter, compared to analyst estimates of $5.33 billion. Equities analysts expect that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current fiscal year.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.